NEW YORK (GenomeWeb News) — Applied Biosystems, Cenix Bioscience, and the Biotechnology Center of Dresden Technical University will create a joint proteomics research facility in Dresden, Germany, Cenix said yesterday.
The German federal government is supporting the facility with q €1.2 million ($1.5 million) grant through its BioChance Plus program.
Cenix, which uses RNAi in drug research, said the two-year partnership will pursue MS-based proteomic analysis of RNAi-induced phenotypes.
The companies will work with the university to analyze gene function and drug action through cellular phenotyping, working to detect and measure effects of pharmaceutical agents that modulate gene expression on living cells.
For the alliance ABI will use its mass spec systems, protein-labeling reagents, gene-expression assays, and RNAi knockdown reagents. The company will also work on the project from its Science Center Europe in Darmstadt, Germany.
Cenix said the project will help to overcome current limits of proteome profiling by developing broad, “quantitative surveys of protein levels in RNAi and drug treated cells using antibody-independent, mass spectrometry-based analyses.